146 related articles for article (PubMed ID: 32770284)
21. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells.
Renner C; Held G; Ohnesorge S; Bauer S; Gerlach K; Pfitzenmeier JP; Pfreundschuh M
Cancer Immunol Immunother; 1997 Apr; 44(2):70-6. PubMed ID: 9177467
[TBL] [Abstract][Full Text] [Related]
22. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
[TBL] [Abstract][Full Text] [Related]
23. Interaction between B.7 and CD28 costimulatory molecules is essential for the activation of effector function mediating spontaneous tumour regression.
Rao KL; Varalakshmi C; Kumari AL; Khar A
Scand J Immunol; 1999 Jun; 49(6):633-40. PubMed ID: 10354375
[TBL] [Abstract][Full Text] [Related]
24. B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas.
Che F; Xie X; Wang L; Su Q; Jia F; Ye Y; Zang L; Wang J; Li H; Quan Y; You C; Yin J; Wang Z; Li G; Du Y; Wang L
Int Immunopharmacol; 2018 Jun; 59():318-327. PubMed ID: 29679856
[TBL] [Abstract][Full Text] [Related]
25. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
28. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
29. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
30. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
31. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
32. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
Ma W; Ma J; Lei T; Zhao M; Zhang M
J Cancer; 2019; 10(21):5153-5161. PubMed ID: 31602268
[TBL] [Abstract][Full Text] [Related]
33. Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody.
Li W; Fan D; Yang M; Yan Y; Shi R; Cheng J; Li Z; Zhang M; Wang J; Xiong D
Hum Gene Ther; 2013 Aug; 24(8):751-60. PubMed ID: 23879717
[TBL] [Abstract][Full Text] [Related]
34. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
35. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.
Andrews K; Hamers AAJ; Sun X; Neale G; Verbist K; Tedrick P; Nichols KE; Pereira S; Geraghty DE; Pillai AB
Cytotherapy; 2020 May; 22(5):276-290. PubMed ID: 32238299
[TBL] [Abstract][Full Text] [Related]
36. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
38. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
[TBL] [Abstract][Full Text] [Related]
39. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
[TBL] [Abstract][Full Text] [Related]
40. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]